395 related articles for article (PubMed ID: 36169332)
41. Immunotyping in tubo-ovarian high-grade serous carcinoma by PD-L1 and CD8+ T-lymphocytes predicts disease-free survival.
Bansal A; Srinivasan R; Rohilla M; Rai B; Rajwanshi A; Suri V; Chandra Saha S
APMIS; 2021 May; 129(5):254-264. PubMed ID: 33455015
[TBL] [Abstract][Full Text] [Related]
42. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
43. Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma.
Kinoshita F; Takada K; Yamada Y; Oku Y; Kosai K; Ono Y; Tanaka K; Wakasu S; Oba T; Osoegawa A; Tagawa T; Shimokawa M; Oda Y; Mori M
Ann Surg Oncol; 2020 Jun; 27(6):2102-2109. PubMed ID: 31773516
[TBL] [Abstract][Full Text] [Related]
44. Biomarker recommendation for PD-1/PD-L1 immunotherapy development in pediatric cancer based on digital image analysis of PD-L1 and immune cells.
Silva MA; Triltsch N; Leis S; Kanchev I; Tan TH; Van Peel B; Van Kerckhoven M; Deschoolmeester V; Zimmermann J
J Pathol Clin Res; 2020 Apr; 6(2):124-137. PubMed ID: 31922656
[TBL] [Abstract][Full Text] [Related]
45. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V
Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332
[TBL] [Abstract][Full Text] [Related]
46. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
47. Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory T cells and macrophages as adverse prognostic factors.
Andersen LB; Nørgaard M; Rasmussen M; Fredsøe J; Borre M; Ulhøi BP; Sørensen KD
J Pathol; 2021 Oct; 255(2):155-165. PubMed ID: 34255349
[TBL] [Abstract][Full Text] [Related]
48. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer.
Flores-Martín JF; Perea F; Exposito-Ruiz M; Carretero FJ; Rodriguez T; Villamediana M; Ruiz-Cabello F; Garrido F; Cózar-Olmo JM; Aptsiauri N
Ann Surg Oncol; 2019 Aug; 26(8):2631-2639. PubMed ID: 31011905
[TBL] [Abstract][Full Text] [Related]
49. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
50. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
51. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens.
Baine MK; Turcu G; Zito CR; Adeniran AJ; Camp RL; Chen L; Kluger HM; Jilaveanu LB
Oncotarget; 2015 Sep; 6(28):24990-5002. PubMed ID: 26317902
[TBL] [Abstract][Full Text] [Related]
52. Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.
Wu J; Sun W; Yang X; Wang H; Liu X; Chi K; Zhou L; Huang X; Mao L; Zhao S; Ding T; Meng B; Lin D
Mod Pathol; 2022 Feb; 35(2):218-227. PubMed ID: 34493824
[TBL] [Abstract][Full Text] [Related]
53. Prognostic Role of Tumoral PD-L1 and IDO1 Expression, and Intratumoral CD8+ and FoxP3+ Lymphocyte Infiltrates in 132 Primary Cutaneous Merkel Cell Carcinomas.
Donizy P; Wu CL; Kopczynski J; Pieniazek M; Biecek P; Ryś J; Hoang MP
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071045
[TBL] [Abstract][Full Text] [Related]
54. Personal immune profiles: Diversity and prognostic value for oral tongue squamous cell carcinoma evaluated by comprehensive immune parameter analyses with multiplex immunofluorescence.
Daroonpan P; Ouchi R; Zhang C; Nagai S; Nishii N; Kashima Y; Tsushima F; Harada H; Hamagaki M; Ikeda T; Aida J; Kaomongkolgit R; Azuma M
Oral Oncol; 2023 Aug; 143():106458. PubMed ID: 37329869
[TBL] [Abstract][Full Text] [Related]
55. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
56. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
57. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
[TBL] [Abstract][Full Text] [Related]
58. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
59. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
60. Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse.
Nardone V; Botta C; Caraglia M; Martino EC; Ambrosio MR; Carfagno T; Tini P; Semeraro L; Misso G; Grimaldi A; Boccellino M; Facchini G; Berretta M; Vischi G; Rocca BJ; Barone A; Tassone P; Tagliaferri P; Del Vecchio MT; Pirtoli L; Correale P
Cancer Biol Ther; 2016 Nov; 17(11):1213-1220. PubMed ID: 27791459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]